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Abstract
Background: Intrachromosomal amplification of chromosome 21 (iAMP21) results from breakage-fusion-bridge
cycles and chromothripsis is a distinct marker of a subgroup of B cell acute lymphoblastic leukemia (B-ALL) cases
associated with a poor prognosis. iAMP21 accounts for 2% of pediatric B-ALL and occurs predominantly in older
children or adolescents. ETV6-RUNX1 fusion, resulting from t(12;21)(p13;q22), is associated with an excellent
outcome in younger children with B-ALL. Coexistence of iAMP21 with ETV6-RUNX1 fusion is extremely rare with
limited clinical information available.
Results: We report the case of an 18-year old Caucasian man diagnosed with ETV6-RUNX1 fusion positive B-ALL. He
was treated with intensive chemotherapy and achieved remission for 6 months before relapse, 15 months after the
initial diagnosis. G-band karyotyping and Fluorescence in situ hybridization (FISH) analyses performed on bone
marrow revealed complex abnormalities: 41,X,-Y,der(3)t(3;20)(p11.2;q11.2),-4,t(5;22)(q32;q11.2),del(9)(p13),dic(9;17)
(p13;p11.2),t(12;21)(p13;q22),der(14)t(14;17)(p11.2;q11.2),der(17;22)(q11.2;q11.2),-20,add(21)(q22),-22[4]/46,XY[15] with
an iAMP21 and an ETV6-RUNX1. Additional molecular studies confirmed ETV6-RUNX1 fusion and with a TP53
mutation. High-resolution single nucleotide polymorphism microarray (SNP array) revealed the iAMP21 to be
chromothripsis of 21q and subsequent metaphase FISH further delineated complex genomic aberrations. Although
the patient received intensive chemotherapy with allogenic stem cell transplant, he died 26 months after initial
diagnosis. We searched the literature and identified six cases showing coexisting iAMP21 and ETV6-RUNX1. The
median age for these six patients was 10 years (range, 2–18) and males predominated. The median overall survival
(OS) was 28 months.
Conclusions: Patients with B-ALL associated with both iAMP21 and ETV6-RUNX1 tend to be older children or
adolescents and have a poor prognosis.
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Background
The latest revision to the World Health Organization
(WHO) classification of B-cell lymphoblastic leukemia/
lymphoma (B-ALL) has added B-ALL with intrachromo-
somal amplification of chromosome 21 (iAMP21) as an
entity in the group of B-ALL with recurrent genetic ab-
normalities [1]. iAMP21 is a distinct marker that can be
readily detected by metaphase FISH [2] and is caused by
breakage-fusion-bridge cycles and chromothripsis, which
is a phenomenon reported in cancer genomes, resulted
from tens to hundreds of genomic rearrangements
occur in a cellular crisis. Chromthripsis can involve one
or more chromosomes, often with massive copy num-
ber aberrations [3]. Recent study suggested that hyper-
ploidy and telomere attrition could be triggering events
for chromothripsis and are frequently associated with
TP53 mutation [4].
B-ALL associated with iAMP21 is a poor prognostic
subgroup that represents 2% of pediatric B-ALL cases.
The median age of patients is 9 years old and there is a
prevalence of males. Patients with iAMP21 often show
low platelet and low white blood cell counts (WBC)
[5–8]. These patients have a relapse rate that is three
times higher than other B-ALL patients are and there-
fore patients often require intensified therapy, particu-
larly in older children or adolescents with B-ALL [9].
The t(12;21)(p13;q22) which results in the formation of
the ETV6-RUNX1 fusion gene accounts for about 25% of
pediatric B-ALL. Patients with B-ALL associated with
ETV6-RUNX1 tend to be younger children and patients
have a favorable outcome [10]. iAMP21 has been reported
rarely in B-ALL associated with ETV6-RUNX1 [11].
In this study, we describe a patient with B-ALL associ-
ated with both iAMP21 with ETV6-RUNX1 that we have
characterized extensively by using molecular and cyto-
genetic methods. We also reviewed the literature and
identified six similar cases [7, 12]. This combination of
molecular alterations in B-ALL tends to occur in older
male patients who have a poor prognosis.
Results
The patient was an 18-year old Caucasian man who pre-
sented initially with pancytopenia. A complete blood
count showed: WBC 2.0 × 109/L, platelets 88 ×109/L
and hemoglobin 8.3 g/dL. Bone marrow examination
showed 61% blasts and the patient was diagnosed with a
B-ALL at another institution (Table 1). FISH studies per-
formed on the bone marrow aspirate smears showed
ETV6-RUNX1 fusion in 28% of interphases with no evi-
dence of BCR-ABL1 or MLL gene rearrangements. No
concurrent chromosome data were available from the
initial bone marrow studies. The patient did not have
central nervous system (CNS) involvement and he was
treated with the intrathecal cytarabine, daunorubicin,
vincristine, intrathecal methotrexate, PEG asparaginase
and prednisone (CALGB 10403 regimen) elsewhere. The
patient did not respond well initially although he eventu-
ally achieved remission for 6 months after a second
round of chemotherapy. The patient then began to show
minimal residual disease by flow cytometry immunophe-
notypic analysis 8 months after the initial diagnosis, and
eventually relapsed 15 months after the diagnosis. The
patient was transferred to our institution at this time
(Table 1).
Table 1 Clinical and laboratory data of the patient
Date 10/9/2013 6/24/2014 12/9/2014 12/31/2014 6/8/2015 8/19/2015
Significant event Initial diagnosis MRD Positive 1st
Relapse
Persistent disease Post-ASCTa 2nd
Relapse
BM Blast (%) (0–5) 61 NA 5 54 1 25
WBC (x109/L) 2.0 5.5 4.6 2.8 5.6 2.2
PLT (x103/μL) 88 383 202 79 133 79
HB (g/dL) 8.3 10.8 13.3 12.9 9.1 11.4
Flow-cytometry analysis Positiveb Positive Positivec Positived NA Positive
G-Band karyotyping NAe NA 46,XY Complex 46,XY 46,XY
ETV6-RUNX1/iAMP21 FISH Positive Negative Borderline Negative Positive NA NA
ETV6-RUNX1 by PCR NA NA NA Positive NA NA
Treatment CALGBf Post- CALGB Blinatumomab Hyper-CVADg + Inotuzumab 50 days Post-ASCT EPOCHh + Rituxan
aPost ASCT post allogeneic stem cell transplantation
bCD19lo, CD22+, cytoplasmic CD79a+, HLA-DR+, aberrant CD13 and CD33 expression, CD3-, CD10-, CD20-, surface Ig-, CD34-, CD38-,MPO-
cCD10+, CD13+, CD19lo, CD33+/lo, CD9-, CD20-, CD34-, surface Ig-
dCD10+, CD13+, CD19+, CD22+,CD33+ (subset), CD45 dim, CD38 dim, CD58, cytoplasmic CD79a, CD81, TdT+, cytoplasmic CD3-, CD15-, CD20-, CD25-, CD34-,
CD66c-, CD117-, CRLF2-, cytoplasmic IgM-, MPO-
eNA not available
fCALGB: IT Cytarabine, Daunorubicin, Vincristine, IT Methotrexate, PEG Asparaginase and Prednisone
gHyper-CVAD: Cyclophosphamide, Vincristine, Doxorubicin Hydrochloride, Dexamethasone
hEPOCH: Etoposide, Vincristine, Cyclophosphamide, Doxorubicin Hydrochloride
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At time of relapse, the complete blood count showed:
WBC 2.8 × 109/L, platelets 79 ×109/L and hemoglobin
12.9 g/dL. Bone marrow examination showed 54% blasts.
Conventional cytogenetic analysis on the relapsed bone




(?;5)(?;?)t(?;22)(?;?),+mar[4]/46,XY[15] as initially reported. A
nuclear fusion of ETV6-RUNX1 signal with RUNX1 amplifi-
cation were observed in 27.5% of the interphases (Fig. 1).
High-resolution SNP microarray revealed losses of chromo-
somes Yq, 3p, 4, 9p, 17p and 20p, as well as chromothripsis-
like pattern of chromosome 21q (Fig. 2). Subsequent meta-
phase FISH analysis on the G-banded chromosomes target-
ing ETV6-RUNX1, DS523/D5S721/EGR1, CSF1R, CDKN2A/
CEP9, TP53/CEP17 and DS20S108 along with whole
chromosome painting (WCP) for chromosomes 17 and 22
(Figs. 3 and 4) showed: 1) a der(3)t(3;20) (p11.2;q11.2)
(D20S108+); 2) a der(5)t(5;22)(q32;q11.2)(WCP22+); 3) a
del(9)(p13) (CDKN2A-,D9Z1+), a dic(9;17)(p13;p11.2)(CDK
N2A-,D9Z1+;D17Z1+,TP53-,WCP17+); 4) a t(12;21)((p13;
(q22)RUNX1+; ETV6+,RUNX1+) and add(21)(RUNX1++
+++); 5) a der(14)t(14;17)(p11.2;q11.2)(WCP17+); 6) a
der(17)t(17;22) (TP53+,D17Z1+,WCP17+,WCP22+); 7)
der((22)t(5;22)(CSF1R+,WCP22+) (Table 2). By integrat-
ing all the SNP array and chromosome and/or metaphase




46,XY[15] (Figs. 3 and 4). In addition, sequencing analysis re-
vealed a 10 base pair deletion-insertion mutation in exon 4
of TP53 (NM_000546(TP53): c.310_321delinsGT p.Q104fs),
resulting in a loss of TP53 function. While this specific muta-
tion is not previously reported in the catalogue of somatic
mutations in cancer (COSMIC), this region in exon 4 is
known to be involved by similar deleterious (frameshift and
Fig. 1 Interphase FISH, metaphase FISH, and SNP microarray analyses. a Interphase FISH showed iAMP21 and ETV6-RUNX1 fusion. b Metaphase
FISH indicated a derivative chromosome 21 with ETV6-RUNX1 fusion, an iAMP21, and a derivative 12 with a single RUNX1 signal. c SNP microarray
showing the chromothripsis-like pattern of chromosome 21q11.2-21q22.3 (15,006,457 – 48,097,372)
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Fig. 2 Chromosome view of SNP microarray analysis showing multiple copy number losses
Fig. 3 Sequential G-banding and metaphase FISH was performed to refine initial karyotyping result. a G-banded metaphase. b Metaphase FISH
indicated ETV6 (green) and RUNX1 (red) fusion as well as RUNX1 amplification. c No deletions for D20S108/20q12 probe in red, one signal on a
normal chromosome 20 and the other signal on the derivative chromosome 3. d No deletions for D5S23/D5S721(5p15.2) in green and EGR1
(5q31) in red). e No rearrangement for CSF1R/ 5q33–34, however, one copy was translocated to chromosome 22. f Homozygous deletion of
CDKN2A (9p21) in red; centromere 9 in green. g Hemizygous deletion of TP53 (17p13.1) in red; centromeric 17 in green. h Whole chromosome
painting (WCP) for 17 (green) stained three different chromosomes, indicated translocations. i WCP for 22 (green) stained three different
chromosomes, indicated translocations
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Fig. 4 Refined karyotype of abnormal metaphase displayed in Fig. 3a with co-localized FISH signals indicated a hypodiploid clone with 1) a
der(3)t(3;20)(p11.2;q11.2)(D20S108+); 2) a der(5)t(5;22)(q32;q11.2)(WCP22+); 3) a del(9)(p13)(CDKN2A-), a dic(9;17)(p13;p11.2)(D9Z1+,CDKN2A-;D17Z1
+,TP53-,WCP17+); 4) a t(12;21)(p13;q22)(RUNX1+; ETV6+,RUNX1+) and add(21)(RUNX1+++++); 5) a der(14)t(14;17)(p11.2;q11.2)(WCP17+); 6) a
der(17)t(17;22) (TP53+,D17Z1+,WCP17+,WCP22+); 7) der(22)t(5;22)(CSF1R+,WCP22+)
Table 2 G-band, FISH, and SNP-array results comparison
Chromosome G-band FISH SNP-array
Y -Y NDa Yp11.31q11.23(2,650,140-28,799,937)x0-1
3 der(3)t(3;20)(p11.2;q11.2) D20S108+ 3p26.3p11.2(61,891-87,302,938)x1-2














17 der(17)t(17;22) TP53+,D17Z1+,WCP17+,WCP22+ 17p13.3q21.32(525-45,059,684)x1 ~ 2
20 −20 disomy for 20q12(D20S108) 20p13q11.21(61,568-29,497,009)x1 ~ 2
21 add(21)(q22) RUNX1+++++ 21q11.2q21.1(15,006,457-19,142,414)x2 ~ 3,





22 -22, t(5;22) t(5;22)(CSF1R+,WCP22+)
aND not done
bNL normal
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truncating) mutations. The patient was treated with blinatu-
momab and the hyper-CVAD (cyclophosphamide, vincris-
tine, doxorubicin, dexamethasone)/inotuzumab regimen, but
only a partial remission was achieved. Due to persistent dis-
ease, the patient eventually received a matched unrelated
donor allogeneic stem cell transplant (ASCT) 19 months
after the initial diagnosis and 6 months after relapse. Unfor-
tunately, the post-transplant course was complicated by liver
veno-occlusive disease and relapse of B-ALL. Despite further
therapy with R-EPOCH (rituximab, etoposide, vincristine,
cyclophosphamide, and doxorubicin) and the patient died
26 months after initial diagnosis.
Discussion
We report the case of an 18-year-old with B-ALL associ-
ated with iAMP21 and ETV6-RUNX1. The patient had a
very poor outcome despite intensified chemotherapy and
allogeneic stem cell transplant. We also searched the lit-
erature and identified six additional cases of B-ALL with
co-existing iAMP21 and the ETV6-RUNX1 [7, 11–14]
(Table 3). The median age of these seven patients was
10 years old (range, 2–18) and the median WBC count
was 9.1 ×109/L (range, 0.7–34.2 ×109/L). Six of seven
(85.7%) cases had karyotypic information with 3 showing
an apparently normal karyotype at the diagnosis, likely the
result of limited blasts dividing in short-term culture. The
remaining 3 cases showed iAMP21 which presented as ei-
ther the “der(21)” or an “add(21)”; 2 of these cases also
had highly complex karyotypes including the current pa-
tient. Four of 7 cases had detailed ETV6/RUNX1 FISH
data (Table 3). Case 1 showed the ETV6-RUNX1 fusion
amplification as a sole finding. Patients 2 and 3 apparently
showed the ETV6-RUNX1 fusion as the primary clone
and iAMP21 as apparent evidence of a clonal evolution.
Interestingly, very similar to the findings as observed in
our case (case 7 in Table 3), patient 4 had the ETV6-
RUNX1 fusion only with a normal karyotype at the
diagnosis, and had the additional iAMP21 in the relapsed
B-ALL. These findings further indicate that iAMP21 is
likely a secondary event that results in disease progression.
OS information is available for 3 of 7 (42.9%) patients;
OS was 34, 28 and 24 months in patients 1, 4 and 7, re-
spectively (Table 3). Patient 1 had a better OS, likely at-
tributable to younger age at the diagnosis. The overall
poor prognosis observed in these patients suggests that
the adverse clinical impact of iAMP21 overrides the










Additional Abnormalities Outcome Treatment References
1 2/M 9.1 NAa Karyotype: 46,XY. FISH: ETV6-RUNX1








2 10/M NA NA RUNX1 amplification with ETV6-RUNX1
fusion in 5.5% cells and without
ETV6-RUNX1 fusion in 88.5% cells
NA NA Case #4
Ma, 2001 [14]
3 2/F 78 98 ETV6-RUNX1 fusion with RUNX1
amplification in 56% cells and without
RUNX1 amplification in 23% cells.
Karyotype: 46,XX
NA NA Case #23
Mikhail, 2002
[13]
4 7/M 34.2 NA At diagnosis: ETV6 deletion with
ETV6-RUNX1 fusion. Normal Karyotype.










5 11/M 0.7 NA Karyotype: 46,XY,add(21)(q22) NA NA Case #528
Harrison, 2014
[7]
6 13/M NA NA Karyotype:
44,XY,del(1)(p33),-4,i(9)(q10),-17, t(19;?)(q13.3;?),dup(21)(q?),+1 ~
2mar[cp16]
NA NA Case #530
Harrison, 2014
[7]
7 18/M 2.0 54 At diagnosis: ETV6-RUNX1 fusion.
No Karyotype.
At relapse: RUNX1 amplification (5 copies)/










dASCT allogeneic stem cell transplantation
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presumably better prognosis associated with ETV6-
RUNX1 in B-ALL.
In the literature, B-ALL associated with iAMP21 is
more frequent than cases of B-ALL with concomitant
iAMP21 and ETV6-RUNX1 fusion. Using an arbitrary
age range for adolescents, we summarized 22 cases of B-
ALL with iAMP21 for comparison. All these 22 patients
had a median age of 15 years at time of diagnosis (range,
13–20) (Table 4) [8, 11, 12, 15, 16] and the male-to-
female ratio was 1.75. Most patients had a low WBC
count with a median of 3.4×9/L (range, 1–15.8). Three
(13.6%) patients had RUNX1 amplification with a normal
karyotype; five (22.7%) patients showed a deletion of
chromosome 7 as an additional abnormality. Clinical fol-
low up data were available in 20 (90.9%) patients show-
ing a median OS of 29.5 months (range, 9–86 months).
Comparing B-ALL with iAMP21 versus B-ALL patients
with coexistent iAMP21 and ETV6-RUNX1, the iAMP21
only patients had a younger age at disease onset; 9 years
old for iAMP21 versus 15 years old for coexistent
iAMP21 and ETV6-RUNX1, p = 0.00. Patients with B-
ALL and iAMP21 only also had a higher WBC count;
25×109/L for iAMP21 only patients versus 5×109/L for
patients with both iAMP21 and ETV6-RUNX1, p = 0.01.
However, OS was insignificant between these two
groups. Although, the clinical data are limited, we be-
lieve that patients with B-ALL associated with iAMP21
and ETV6-RUNX1 can be included in the cytogenetic
subgroup of “iAMP21”.
In addition to the co-existing of ETV6-RUNX1 fusion
and iAMP21, our patient also showed TP53 deletion with
a concomitant TP53 mutation. TP53 deletion is frequently
observed in B-ALL, particularly in those with hypodip-
loidy or familial Li Fraumeni syndrome or cancer predis-
position syndrome [17]. Sequencing methods allow
identification and better characterization of TP53 muta-
tion in 90% hypodiploid childhood ALL that is important
for prognostic assessment [18, 19]. The concomitant TP53
mutation with deletion could result in “two hits” for TP53
loss of function and could result in poorer prognosis in





Additional Abnormalities RUNX1 Copies/
Cell
Outcome References
1 15/M 3.1 −8,der(16)t(1;16),−21 5–6 CRb1 × 9 months Johnson, 2015
[11]
2 17/M 2.4 Normal Karyotype >5 Relapsed 58 months after diagnosis following
SCT, CR2 × 3 y
Johnson, 2015
[11]
3 20/M 2.2 −13,−14,+21 6–7 CR1 × 30 months Johnson, 2015
[11]
4 19/M 5.3 del(7)(q11.2) 5–9 CR alive for 2 years Knez, 2015 [15]
5 13/M 3.7 None 5–10 Unknown Knez, 2015 [15]
6 15/M 2.1 None 4–8 Relapsed after 7 years of CR Knez, 2015 [15]
7 13/F 3.0 +X >5 CR and alive for 3 years Knez, 2015 [15]




9 14/M 2.2 None 5–10 CR 29 months Reichard, 2011 [8]
10 15/M 2.0 Not Done 6–8 CR 51 months Reichard, 2011 [8]
11 13/F 2.8 None 5–10 CR 18 months Soulier, 2003 [16]
12 17/M 1.0 add(1)(q25) 8 CR 19 months Soulier, 2003 [16]
13 19/F 10.1 del(7)(p14p21) 6–8 CR 21 months Soulier, 2003 [16]
14 14/M 2.2 inv(7)(p?15q?21) 5–7 CR 23 months Soulier, 2003 [16]
15 13/F 3.8 del(7)(q22q35),del(11)(p12) 5 CR 61 months Soulier, 2003 [16]
16 15/F 9.9 None 4 CR 86 months Soulier, 2003 [16]
17 15/M 4.3 -Y 4–5 CR 32 months Soulier, 2003 [16]
18 15/F NAa add(1)(p?),del(6)(q25) >4 CR 13 months Soulier, 2003 [16]
19 13/M 7.6 i(9)(q10),−16 4 CR 18 months Soulier, 2003 [16]
20 13/F 6.6 add(4)(q31),del(7)(q3?2) 5 CR 10 months Soulier, 2003 [16]
21 14/M 14.5 Normal Karyotype 6–15 CR 48 months Soulier, 2003 [16]
22 15/F NA Normal Karyotype 15–20 Relapsed Soulier, 2003 [16]
aNA not available
bCR complete remission
Gu et al. Molecular Cytogenetics  (2016) 9:84 Page 7 of 10
our patient [20]. In addition, the null-function of TP53 or
other tumor suppressor gene, such as the homozygous
CDKN2A deletions observed in our patient, can also pro-
mote the chromothripsis of 21q at the genomic level [21].
Hetero- or homozygous deletions of CDKN2A are recur-
rent findings in pediatric ALL. However, they are often
considered as secondary events in childhood ALL and in-
crease the likelihood of relapse [22, 23]. In our patient, the
CDKN2A homozygous deletions were likely following the
ETV6-RUNX1 fusions, to drive disease progression to-
gether with the iAMP21.
iAMP21 is also a chromothripsis phenomenal, resulted
in the remodeling chromosome 21 in a nonrandom fash-
ion, leading to a stable derivative of chromosome 21
with leukemic potential [6]. Recent studies have pro-
vided new insight about the mechanistic events and con-
sequences of chromothripsis [4, 24, 25]. These non-
random genomic instabilities of chromosome 21q could
be an initial leukemic event [26] in B-ALL pathogenesis,
although it was a secondary event in our patient. The
additional segmental copy number aberrations involving
other parts of the genome, often reflected by complex
karyotypes, are likely a secondary event in pathogenesis.
High-resolution microarray based testing integrated with
traditional chromosome/FISH analysis, particularly the
metaphase FISH as performed in our patient, would
allow the refinement of the heterogeneous karyotypic
findings in iAMP21 B-ALL cases. The clinically critical
regions of iAMP21 likely within the 21q22.2-22q22.3 re-
gion encoding for 19 to 32 Mb [26–31] in size. These
genomic complexities likely contribute to the tumor pro-
gression and the poor response to therapy in this subset
of the B-ALL patients.
Conclusions
Our results suggest that the coexistence of iAMP21 and
ETV6-RUNX1 fusion B-ALL is associated with relatively
older age, male predominance, and a very poor progno-
sis. The presence of ETV6-RUNX1 does not appear to
modify the poor prognosis imparted by iAMP21 in B-
ALL. Older children with an ETV6-RUNX1 fusion posi-
tive B-ALL should be monitored closely for the develop-
ment of iAMP21, particularly when a relapse of B-ALL
is suspected. Patients with B-ALL associated with both
iAMP21 and ETV6-RUNX1 fit best in the poor progno-
sis cytogenetic subgroup of “iAMP21”. Integrated gen-
omic testing including high-resolution microarray and




Eight- color flow cytometric immunophenotypic analysis
was performed according to standard procedures. The
panel included antibodies directed against: CD3, CD4,
CD5, CD7, CD9, CD10, CD13, CD19, CD20, CD22,
CD25, CD33, CD34, CD38, CD52, CD79a, CD117, BCL-
2, HLA-DR, myeloperoxidase, IgM (cytoplasmic), kappa
and lambda light chains (Becton-Dickinson Biosciences,
San Jose, CA, USA), TdT (Supertechs Inc, Bethesda,
MD, USA).
Cytogenetic and FISH analysis
Twenty-four and/or forty-eight hour unstimulated bone
marrow cultures were setup for conventional cytogenetic
analysis. Using a Leica-microscope imaging system
(Leica Microsystems Inc., Chicago, IL) 20 metaphases
were examined and karyotypes were prepared according
to International System for Human Cytogenetic Nomen-
clature (ISCN 2013).
FISH studies were performed on cultured bone mar-
row metaphases and interphases using the probe sets
targeting ETV6/RUNX1, BCR/ABL1(ES), MLL, CDKN2A
/CEP9, D5S23/D5S721/EGR1, TP53/CEP17, D20S108
(Abbott Molecular, Inc. Abbott Park, IL); and CSF1R
break-apart (5q32), WCP17, WCP22 (Cytocell Ltd,
OGT, UK). A G-banded slide was destained in methanol
and hybridized with all the FISH probes above subse-
quently, according to standard lab procedures. FISH im-
ages were then captured in Cytovision and 200 cells
were scored by two technologists when applicable.
SNP microarrays
SNP microarray study was performed using the Affyme-
trix CytoScan HD array (Affymetrix, Inc. Santa Clara,
CA) which contains 2.5 million markers, including
750,000 SNPs and 1.7 million non-polymorphic probes,
with extensive coverage over 18,500 RefSeq genes,
known cancer genes and 12,000 OMIM genes. In brief,
250 ng of genomic DNA for each NK cell line were hy-
bridized to a CytoScan HD array according to the manu-
facturer’s protocols. Array data for copy number
alterations (CNAs) and copy-neutral loss of heterozygos-
ity (cnLOH) were analyzed using Affymetrix Chromo-
some Analysis Suite v.3.1 (ChAS) software and the
Nexus copy number 7.5 (BioDiscovery Inc, El Segundo,
CA) with a reference framework of NA33 (hg19). Re-
gions of copy number alterations larger than 50
markers/400 kb for gain or 20 markers/100 kb for loss
and copy neutral loss of heterozygosity (LOH) larger
than 3 Mb are recorded. All CNAs were compared
with known public databases of normal genomic vari-
ants (DGV).
Molecular study
Nanofluidics-based qualitative multi-parametric reverse-
transcriptase polymerase chain reaction (PCR) was
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performed for the detection of ETV6-RUNX1 fusion
transcripts. PCR-based DNA sequencing was performed
to assess for mutations in exons 4 to 9 (codons 33 to
331) of TP53.
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